- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
CYNK-001 Granted Orphan Drug Designation for Treatment of Malignant Gliomas
April 13, 2021
The FDA has granted orphan drug designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the treatment of patients with malignant gliomas.
Roundtable Discussion: Fonseca Leads Debate on the Use of Minimal Residual Disease in Multiple Myeloma
April 13, 2021
During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma
REACH-2: Ruxolitinib Is Viable Option in Steroid-Refractory Acute GVHD
April 13, 2021
Experts decide whether ruxolitinib is a viable treatment option for steroid-refractory acute graft-versus-host-disease based on the case of a 48-year-old patient.
Breast Cancer Testing May Benefit from the Multi-Omics Approach Over Biomarker Assessment Alone
April 13, 2021
For patients with metastatic breast cancer, research suggests that utilizing a multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data may be feasible and better than DNA sequencing alone.
Lenalidomide Reduces Infection Mortality Rates in COVID-19-Positive Patients With Multiple Myeloma
April 13, 2021
Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.
Clinical Pearls for the Management of MM
April 13, 2021
An expert in multiple myeloma provides clinical pearls for disease management from initial diagnosis through multiple lines of therapy.
The Evolving Treatment Landscape in MM
April 13, 2021
Dr. Natalie Callander describes promising new treatment approaches for patients with multiple myeloma.
Considerations for Third-Line Therapy in MM
April 13, 2021
An expert in multiple myeloma talks through the considerations for treatment selection in the third line for patient with multiple myeloma.
Second-Line Options After ASCT in MM
April 13, 2021
Dr. Natalie Callander provides insight on selection of second-line therapy after transplant patients with multiple myeloma.
Case Presentation: A 68-Year-Old Man With Multiple Myeloma
April 13, 2021
Natalie Callander, MD presents a case of a 68-year-old man with multiple myeloma and reviews first-line treatment options.
Telisotuzumab Vedotin Shows Promising Efficacy and Safety Results for c-Met+ NSCLC
April 13, 2021
Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.
D-0316 Shows Clinically Meaningful Improvement in Patients with T790M+ and EGFR+ NSCLC
April 12, 2021
More than half of patients with T790M-positive non-small cell lung cancer had a response to the third generation EGFR TKI D-0316 in a phase 2 study.